Speaker
Description
Prostate cancer incidence is projected to nearly double worldwide, from 1.4 million cases in 2020 to 2.9 million by 2040, with the greatest proportional increase occurring in low- and middle-income countries (LMICs). Late-stage presentation remains the norm in these settings, driving higher mortality despite the availability of effective diagnostic and therapeutic strategies. A recent Lancet Commission highlights the urgent need for resource-adapted diagnostic pathways, including the integration of advanced imaging modalities such as prostate-specific membrane antigen (PSMA) PET, which offers improved staging accuracy and potential cost-effectiveness when appropriately deployed. Strategic implementation of PSMA PET, alongside education and early detection programs, represents a key opportunity to shift diagnosis toward earlier stages and improve outcomes in LMICs.
| Track | Deployment of Nuclear Medicine in LMICs: Enabling Technologies |
|---|---|
| Presentation type | Oral |